JPWO2021214658A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021214658A5 JPWO2021214658A5 JP2022563971A JP2022563971A JPWO2021214658A5 JP WO2021214658 A5 JPWO2021214658 A5 JP WO2021214658A5 JP 2022563971 A JP2022563971 A JP 2022563971A JP 2022563971 A JP2022563971 A JP 2022563971A JP WO2021214658 A5 JPWO2021214658 A5 JP WO2021214658A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- optionally
- weeks
- storage
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013801P | 2020-04-22 | 2020-04-22 | |
| US63/013,801 | 2020-04-22 | ||
| PCT/IB2021/053254 WO2021214658A1 (en) | 2020-04-22 | 2021-04-20 | Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetil-15) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023523218A JP2023523218A (ja) | 2023-06-02 |
| JP2023523218A5 JP2023523218A5 (https=) | 2024-04-30 |
| JPWO2021214658A5 true JPWO2021214658A5 (https=) | 2024-04-30 |
Family
ID=75639945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563971A Pending JP2023523218A (ja) | 2020-04-22 | 2021-04-20 | ヘテロ二量体ヒトインターロイキン－１５（ｈｅｔＩＬ－１５）の医薬組成物及び医薬製品 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210330747A1 (https=) |
| EP (1) | EP4138782A1 (https=) |
| JP (1) | JP2023523218A (https=) |
| KR (1) | KR20230004655A (https=) |
| CN (1) | CN115443127A (https=) |
| AR (1) | AR122428A1 (https=) |
| AU (1) | AU2021260989A1 (https=) |
| BR (1) | BR112022020973A2 (https=) |
| CA (1) | CA3178895A1 (https=) |
| CO (1) | CO2022014867A2 (https=) |
| IL (1) | IL297326A (https=) |
| MX (1) | MX2022013352A (https=) |
| TW (1) | TW202214290A (https=) |
| WO (1) | WO2021214658A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118284620A (zh) * | 2021-11-18 | 2024-07-02 | 山东先声生物制药有限公司 | 一种il-15突变体融合蛋白药物组合物 |
| KR20250144433A (ko) * | 2023-02-14 | 2025-10-10 | 아크론 바이오프로덕츠 엘엘씨 | 생체내 이용을 위한 인터루킨 제형물 |
| CN117883565A (zh) * | 2023-12-25 | 2024-04-16 | 中山大学 | 沙美特罗和pd-1抗体联用在制备治疗黑色素瘤的药物中的应用 |
| WO2025206413A1 (en) * | 2024-03-28 | 2025-10-02 | The University Of Tokyo | Protein-enclosing polymeric complexes |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| EP3263581B2 (en) | 2005-05-17 | 2025-07-09 | University of Connecticut | Compositions and methods for immunomodulation in an organism |
| EP2366787B1 (en) | 2006-01-13 | 2019-12-11 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells |
| DK2160401T3 (da) | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
| WO2009090189A1 (en) * | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co.Kg | Powdered protein compositions and methods of making same |
| KR101577849B1 (ko) | 2008-08-22 | 2015-12-15 | 마그나 시팅 인크. | 감소된 백래쉬를 갖는 디스크 리클라이너 |
| CN104689426B (zh) * | 2009-10-21 | 2018-10-02 | 欧文蒙福德有限公司 | 自动注射器 |
| CN107880136B (zh) | 2010-09-21 | 2021-11-12 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| EP2958588B1 (en) * | 2013-02-22 | 2017-08-23 | CureVac AG | Combination of vaccination and inhibition of the pd-1 pathway |
| WO2016018920A1 (en) * | 2014-07-29 | 2016-02-04 | Admune Therapeutics Llc | Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions |
| WO2017177063A1 (en) * | 2016-04-06 | 2017-10-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of heterodimeric il-15 in adoptive cell transfer |
| UA125971C2 (uk) * | 2017-07-25 | 2022-07-20 | Джянгсу Хенгруй Медісін Ко., Лтд. | Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування |
| EP3810171B1 (en) * | 2018-06-22 | 2025-07-09 | Cugene Inc. | Novel interleukin-15 (1l-15) fusion proteins and uses thereof |
| JP2022530130A (ja) * | 2019-04-26 | 2022-06-27 | ルビウス セラピューティクス， インコーポレイテッド | 除核赤血球細胞を含む緩衝組成物 |
-
2021
- 2021-04-20 IL IL297326A patent/IL297326A/en unknown
- 2021-04-20 CA CA3178895A patent/CA3178895A1/en active Pending
- 2021-04-20 AU AU2021260989A patent/AU2021260989A1/en active Pending
- 2021-04-20 CN CN202180030326.7A patent/CN115443127A/zh active Pending
- 2021-04-20 TW TW110114219A patent/TW202214290A/zh unknown
- 2021-04-20 MX MX2022013352A patent/MX2022013352A/es unknown
- 2021-04-20 JP JP2022563971A patent/JP2023523218A/ja active Pending
- 2021-04-20 KR KR1020227040050A patent/KR20230004655A/ko active Pending
- 2021-04-20 BR BR112022020973A patent/BR112022020973A2/pt unknown
- 2021-04-20 EP EP21720852.9A patent/EP4138782A1/en active Pending
- 2021-04-20 WO PCT/IB2021/053254 patent/WO2021214658A1/en not_active Ceased
- 2021-04-20 US US17/234,914 patent/US20210330747A1/en active Pending
- 2021-04-22 AR ARP210101082A patent/AR122428A1/es unknown
-
2022
- 2022-10-19 CO CONC2022/0014867A patent/CO2022014867A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2312179T3 (es) | Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1. | |
| ES2344729T3 (es) | Interleuquina 2 estabilizada. | |
| US20190071496A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| JP2024075713A5 (https=) | ||
| ES2450592T3 (es) | Uso de ulipristal para tratar los fibroides uterinos | |
| JP2024099628A5 (https=) | ||
| JP2012515170A5 (https=) | ||
| AU2004218808A1 (en) | Pharmaceutical preparations comprising acid-stabilised insulin | |
| ES3031633T3 (en) | Annexin a1 n-terminal peptide formulations and methods | |
| RU2015147876A (ru) | Пероральная дозированная форма соединений глюкагоноподобного пептида-1 | |
| ES2774296T3 (es) | Terapias de combinación para tratar cánceres quimiorresistentes | |
| CA2573512A1 (en) | Compositions for delivering peptide yy and pyy agonists | |
| TW201219051A (en) | Pharmaceutical composition | |
| RU2749342C1 (ru) | Фармацевтическая композиция на основе белкового комплекса il-15 и ее применения | |
| JP2010511665A5 (https=) | ||
| CN108350458B (zh) | 用豹蛙酶和/或两栖酶治疗病毒性结膜炎 | |
| CN114652825A (zh) | 稳定的抗体制剂及其制备方法和应用 | |
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| JPWO2021214658A5 (https=) | ||
| ECSP055960A (es) | Formulaciones parenterales de un péptido para el tratamiento de lupus sistémico eritematoso | |
| EP3996680B1 (en) | Stable formulations of recombinant proteins | |
| JP2008502323A5 (https=) | ||
| ES2215027T3 (es) | Composiciones de proteinas de matrices destinadas a inducir la apoptosis. | |
| JP2026502943A (ja) | 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法 | |
| RU2690677C1 (ru) | Стабилизированная композиция, обладающая противовирусной, противоопухолевой, иммуномодулирующей, актопротекторной, антимутагенной и антиоксидантной активностью |